Trial Profile
Efficacy and Safety of Lenalidomide with R-IMED (rituximab, ifosfamide, methotrexate, etoposide and dexamethasone) in refractory or relapsed non-GCB diffuse large B-cell lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jun 2018
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Etoposide (Primary) ; Ifosfamide (Primary) ; Lenalidomide (Primary) ; Methotrexate (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 28 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.